Bicycle Therapeutics (STU:50BA) Beneish M-Score: -1.51 (As of Jun. 24, 2026)


STU:50BA Bicycle Therapeutics PLC STU:50BA
54 GF Score
Price €3.48
GF Value €13.23
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Bicycle Therapeutics Beneish M-Score?

Bicycle Therapeutics STU:50BA +1.16% 54 Beneish M-Score is -1.51 as of Jun. 24, 2026. GuruFocus rates STU:50BA with a GF Score™ of 54/100 and a GF Value™ of €13.23 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 831 Biotechnology companies, Bicycle Therapeutics ranks worse than 71.6% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score -1.51 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for Bicycle Therapeutics's Beneish M-Score or its related term are showing as below:

STU:50BA' s Beneish M-Score Range Over the Past 10 Years
Min: -3.89   Med: -2.34   Max: 1.73
Current: -1.51

During the past 9 years, the highest Beneish M-Score of Bicycle Therapeutics was 1.73. The lowest was -3.89. And the median was -2.34.


Bicycle Therapeutics Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Bicycle Therapeutics's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bicycle Therapeutics Beneish M-Score Chart

Bicycle Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only -2.89 -1.61 -3.15 -1.87 -1.59

Bicycle Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.04 -1.30 -2.28 -1.59 -1.51

STU:50BA vs ABEO, DMAC, FATE: Beneish M-Score Comparison

For the Biotechnology subindustry, Bicycle Therapeutics's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bicycle Therapeutics Beneish M-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bicycle Therapeutics's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Bicycle Therapeutics's Beneish M-Score falls into.


STU:50BA
54GF Score
Bicycle Therapeutics PLC STU:50BA
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bicycle Therapeutics Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Bicycle Therapeutics for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.3631+0.528 * 1+0.404 * 1.4241+0.892 * 2.2721+0.115 * 1.4083
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.4113+4.679 * 0.013875-0.327 * 1.4118
=-1.68

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was €35.39 Mil.
Revenue was 0.767 + 40.954 + 9.997 + 2.532 = €54.25 Mil.
Gross Profit was 0.767 + 40.954 + 9.997 + 2.532 = €54.25 Mil.
Total Current Assets was €535.55 Mil.
Total Assets was €564.32 Mil.
Property, Plant and Equipment(Net PPE) was €17.53 Mil.
Depreciation, Depletion and Amortization(DDA) was €5.08 Mil.
Selling, General, & Admin. Expense(SGA) was €65.88 Mil.
Total Current Liabilities was €42.29 Mil.
Long-Term Debt & Capital Lease Obligation was €12.00 Mil.
Net Income was -52.614 + -17.212 + -50.353 + -68.451 = €-188.63 Mil.
Non Operating Income was 0.093 + -0.044 + 0.135 + 0.646 = €0.83 Mil.
Cash Flow from Operations was -57.025 + -16.521 + -60.639 + -63.105 = €-197.29 Mil.
Total Receivables was €42.90 Mil.
Revenue was 9.229 + 3.541 + 2.411 + 8.696 = €23.88 Mil.
Gross Profit was 9.229 + 3.541 + 2.411 + 8.696 = €23.88 Mil.
Total Current Assets was €791.88 Mil.
Total Assets was €817.60 Mil.
Property, Plant and Equipment(Net PPE) was €14.29 Mil.
Depreciation, Depletion and Amortization(DDA) was €6.62 Mil.
Selling, General, & Admin. Expense(SGA) was €70.50 Mil.
Total Current Liabilities was €53.30 Mil.
Long-Term Debt & Capital Lease Obligation was €2.41 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(35.393 / 54.25) / (42.896 / 23.877)
=0.652406 / 1.796541
=0.3631

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(23.877 / 23.877) / (54.25 / 54.25)
=1 / 1
=1

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (535.552 + 17.533) / 564.323) / (1 - (791.88 + 14.289) / 817.602)
=0.019914 / 0.013984
=1.4241

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=54.25 / 23.877
=2.2721

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(6.619 / (6.619 + 14.289)) / (5.084 / (5.084 + 17.533))
=0.316577 / 0.224787
=1.4083

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(65.882 / 54.25) / (70.502 / 23.877)
=1.214415 / 2.952716
=0.4113

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((12.001 + 42.289) / 564.323) / ((2.413 + 53.301) / 817.602)
=0.096204 / 0.068143
=1.4118

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-188.63 - 0.83 - -197.29) / 564.323
=0.013875

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Bicycle Therapeutics has a M-score of -1.68 signals that the company is likely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -1.51 mean?
Bicycle Therapeutics (STU:50BA) has a Beneish M-Score of -1.51 as of Jun. 24, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Bicycle Therapeutics and its competitors. According to the industry distribution chart, Bicycle Therapeutics ranks #595 out of 831 companies in the Biotechnology industry, placing it in the top 71.6%.
Is Bicycle Therapeutics' Beneish M-Score too high?
Bicycle Therapeutics' current Beneish M-Score is -1.51. Based on the distribution chart, Bicycle Therapeutics ranks #595 out of 831 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Bicycle Therapeutics has a GF Score™ of 54/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Bicycle Therapeutics' Beneish M-Score compare to ABEO and DMAC?
According to the Biotechnology industry distribution chart, Bicycle Therapeutics ranks #595 out of 831 companies for Beneish M-Score. This places Bicycle Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Biotechnology company?
A good Beneish M-Score depends on the Biotechnology industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Bicycle Therapeutics and its competitors. Bicycle Therapeutics's current Beneish M-Score is -1.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bicycle Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Bicycle Therapeutics (STU:50BA) is currently considered Possible Value Trap. The stock's GF Value™ is €13.23, compared to a current price of €3.48 — trading 73.7% below its estimated fair value. The current Beneish M-Score is -1.51. Bicycle Therapeutics' overall GF Score™ is 54/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Bicycle Therapeutics (STU:50BA), the current Beneish M-Score is -1.51 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bicycle Therapeutics (STU:50BA) Overvalued in 2026?

Based on GuruFocus' analysis, Bicycle Therapeutics stock appears to be undervalued. The current stock price of €3.48 is trading 73.7% below its estimated GF Value™ of €13.23. GuruFocus considers Bicycle Therapeutics to be Possible Value Trap.

Key valuation signals for STU:50BA:

  • Beneish M-Score: -1.51
  • GF Value™: €13.23 vs. price of €3.48 (73.7% below fair value)
  • GF Score™: 54/100 with 5 warning signs

No single metric tells the full story. See the STU:50BA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Bicycle Therapeutics Business Description

Other Exchanges BCYC:USA
Address Granta Park, Great Abington, Blocks A and B, Portway Building, Cambridge, GBR, CB21 6GS
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United Kingdom.
54GF Score

Get the complete analysis for STU:50BA

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.48
Price
€13.23
GF Value